Work

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-165795

Authors: Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, Michael R. Grever

Institutions: The Ohio State University, University of New Mexico, UNM Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute, Mayo Clinic, The University of Texas MD Anderson Cancer Center, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310126637

FWCI: 0.509

Cites:

Cited by: 4

Related to: 10